Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Arizona Joins States Enacting Opioid Prescribing Restrictions

    by
    • Optum Workers' Comp
    | Feb 22, 2018
    Tag Icon
    Opioids
    Arizona’s Governor recently signed into law Senate Bill 1001 which, among other changes, establishes several new requirements for prescribing and dispensing opioids. Most notably, Arizona has gone the route of several other states over the last couple of years by enacting days’ supply and morphine milligram equivalent (MME) limits on prescriptions for these medications.


  • Purdue no longer promoting OxyContin® to doctors

    by
    • Optum Workers' Comp
    | Feb 13, 2018
    Tag Icon
    Opioids
    Purdue Pharma LP announced it will no longer actively promote OxyContin® to doctors. Following its launch in 1996, Purdue marketed the pain medication to doctors to prescribe for patients with pain. In workers’ compensation, OxyContin has been one of the most widely prescribed and highest ranked long-acting opioid analgesic in terms of medication spend in the past decade.


  • Localized shortages of Nucynta® products reported

    by
    • Optum Workers' Comp
    | Feb 05, 2018
    Tag Icon
    Opioids
    Following the devastation and power outages in Puerto Rico from Hurricane Maria, Depomed issued a press release indicating there may be temporary delays in the packaging and delivery of Nucynta® ER (tapentadol extended-release). Certain dosage strengths are being manufactured by the company’s third-party partner located on the island and those dosages would be potentially affected. The company reported that it did not expect any disruption to the supply of the immediate-release (IR) formulation of Nucynta.


  • New drug therapy approvals in 2017

    by
    • Optum Workers' Comp
    | Feb 01, 2018
    Tag Icon
    The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has published their annual report, Advancing Health through Innovation: New Drug Approvals and Other Drug Therapy Advances of 2017. This report not only summarizes the approval of 46 new medications in 2017, it also provides information on the CDER’s role in supporting the FDA’s efforts to endorse innovation, efficiently execute the review and approval of new medications while maintaining patient safety, and improve various treatments for patients






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.